ClinicalTrials.gg
CompletedNCT00930514Updated Nov 2, 2016

A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

A Phase 1 interventional study of Rituximab and Rituximab in Lymphoma, Follicular, sponsored by Hoffmann-La Roche. Completed at 62 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
281
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.

Enrollment
29th of 188
281 · median 48
Started
2009
with 13 others
Phase 1
27 of 194
1 open now
Registered
115th of 194
by date
Lead sponsor
4 of 194
Hoffmann-La Roche

Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 29th largest by enrollment of the 188 interventional ones that give a count, is one of 14 that started in 2009, is one of 27 in phase 1, and was the 115th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 290 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies testing rituximab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This 2 stage study will compare the pharmacokinetics and safety profile of subcutaneous and intravenous rituximab in participants with follicular lymphoma. In the first stage, participants who have achieved at least a partial response after induction treatment with intravenous rituximab will be randomized to one of 3 treatment cohorts, to receive rituximab 375 milligram per square meter (mg/m\^2) intravenously, 375 mg/m\^2 subcutaneously or 625 mg/m\^2 subcutaneously, and pharmacokinetics evaluated on an ongoing basis. Upon selection of the subcutaneous dose (800 mg/m\^2) which results in rituximab trough plasma concentration (C trough) values comparable to those achieved with the intravenous formulation, participants in the second stage of the study will be randomized to receive either the subcutaneous or intravenous formulation to demonstrate comparability of the C trough levels with both routes of administration. Maintenance therapy will continue every 2 or 3 months with the subcutaneous formulation.

03

Conditions studied

  • Lymphoma, Follicular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CD20-positive follicular non-Hodgkin's lymphoma (NHL)
  • Documented partial or complete response a the end of induction treatment with rituximab
  • Must have completed induction treatment, and received at least 1 dose of intravenous rituximab maintenance treatment
  • (ECOG) performance status of less than and equal to (\<=) 2
  • of greater than and equal to (>=) 6 months

Exclusion criteria

Exclusion Criteria:

  • Histological evidence of transformation of NHL, or types of NHL other than follicular lymphoma
  • Presence or history of central nervous system disease
  • History of other than follicular NHL
  • Recent major surgery (within 4 weeks prior to screening), excluding lymph node
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
281 participants (actual)

Study arms

  • Active comparator
    Rituximab IV 375 mg/m^2 (Stage 1: Cohort A)

    Drug: Rituximab

  • Active comparator
    Rituximab IV 375 mg/m^2 (Stage 2: Cohort E)

    Drug: Rituximab

  • Experimental
    Rituximab SC 1400 mg (Stage 2: Cohort F)

    Drug: Rituximab

  • Experimental
    Rituximab SC 375 mg/m^2 (Stage 1: Cohort B)

    Drug: Rituximab

  • Experimental
    Rituximab SC 625 mg/m^2 (Stage 1: Cohort C)

    Drug: Rituximab

  • Experimental
    Rituximab SC 800 mg/m^2 (Stage 1: Cohort D)

    Drug: Rituximab

Interventions

  • Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.

  • Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.

    Also known as: MabThera/Rituxan

  • Rituximab subcutaneous injection 625 mg/m\^2 administered every 2 or 3 months.

    Also known as: MabThera/Rituxan

  • Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.

    Also known as: MabThera/Rituxan

  • Rituximab subcutaneous injection 375 mg/m\^2 administered every 2 or 3 months.

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Minimum Observed Plasma Trough Concentration (C trough)

    Time frame: Up to 29 months

Secondary outcomes

  1. Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)

    Time frame: Up to 29 months

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to 29 months

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Up to 29 months

  4. Plasma Decay Half-Life (t1/2)

    Time frame: Up to 29 months

  5. Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

    Time frame: Up to 29 months

07

Study locations

62 sites
  • Buenos Aires, 1425, Argentina
  • Buenos Aires, C1114AAN, Argentina
  • Buenos Aires, C1221ADC, Argentina
  • Córdoba, 5000, Argentina
  • Rosario, 2000, Argentina
  • Kogarah, New South Wales 2217, Australia
  • Sydney, New South Wales 2139, Australia
  • Kurralta Park, South Australia 5037, Australia
  • Fitzroy, Victoria 3065, Australia
  • Porto Alegre, RS 91350-200, Brazil
  • Barretos, SP 14784-400, Brazil
  • Sao Paulo, SP 05403-000, Brazil
  • Sao Paulo, SP 05652-000, Brazil
  • Calgary, Alberta T2N 4N2, Canada
  • St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Halifax, Nova Scotia B3H 2Y9, Canada
  • Montreal, Quebec H3T 1E2, Canada
  • Quebec, G1J 1Z4, Canada
  • Brno, 625 00, Czech Republic
  • Hradec Kralove, 500 05, Czech Republic
  • Praha 2, 128 08, Czech Republic
  • Herlev, 2730, Denmark
  • Guayaquil, EC090114, Ecuador
  • Quito, 2569, Ecuador
  • Helsinki, 00029, Finland
  • Tampere, 33520, Finland
  • Turku, 20520, Finland
  • Marseille, 13273, France
  • Montpellier, 34295, France
  • Reims, 51092, France
  • Haifa, 3109601, Israel
  • Jerusalem, 9112001, Israel
  • Petach Tikva, 49100, Israel
  • Ramat Gan, 52662, Israel
  • Bergamo, Lombardia 24127, Italy
  • Milano, Lombardia 20162, Italy
  • Torino, Piemonte 10126, Italy
  • Pisa, Toscana 56100, Italy
  • Seoul, 135-710, Korea, Republic of
  • Aguascalientes, 20127, Mexico
  • Mexico City, Distrito Federal, 14050, Mexico
  • Monterrey, 64460, Mexico
  • Oslo, 0379, Norway
  • Lima, 11, Peru
  • Lima, 34, Peru
  • Warszawa, 02 776, Poland
  • Wroclaw, 50-367, Poland
  • Moscow, 115478, Russian Federation
  • Bratislava, 833 10, Slovakia
  • Barcelona, 08003, Spain
  • Barcelona, 08036, Spain
  • Salamanca, 37007, Spain
  • Sevilla, 41013, Spain
  • Huddinge, 14186, Sweden
  • Sundsvall, 85186, Sweden
  • Umea, 90185, Sweden
  • Uppsala, 75185, Sweden
  • Basel, 4031, Switzerland
  • Cambridge, CB2 0QQ, United Kingdom
  • London, EC1A 7BE, United Kingdom
  • Manchester, M20 4QL, United Kingdom
  • Nottingham, NG5 1PB, United Kingdom
08

References and documents

Publications

  • Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014 Jun 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. Epub 2014 May 12. PubMed 24821885 ↗
  • Mao CP, Brovarney MR, Dabbagh K, Birnbock HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One. 2013 Nov 12;8(11):e80533. doi: 10.1371/journal.pone.0080533. eCollection 2013. PubMed 24265828 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2009
First posted
Jun 30, 2009
Start
Sep 2009
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00930514
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 30, 2009
Start date
Sep 2009
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion